Venmax Drugs & Pharmaceuticals Ltd
Incorporated in 1998, Venmax Drugs & Pharmaceuticals Ltd is engaged in the business of IT & ITES services[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Documents
Announcements
-
Board Meeting Intimation for Unaudited Financial Results Of The Company For The Quarter Ended June 30, 2025.
2d - Board meeting on July 23 to approve Q1 June 30, 2025 un-audited results; trading window closed till July 25.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Jul - Certificate under Regulation 74(5) of the SEBI (Depositories and Participants Regulations, 2018 for the quarter ended June 30, 2025.
-
Closure of Trading Window
27 Jun - Trading window closed from July 1, 2025, before Q1 FY26 financial results announcement.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
10 May - Listing Regulations, 2015, enclosed here with copies of Newspaper publications providing Audited financial results for the Quarter and Year ended March 31st, 2025.
-
Integrated Filing (Financial)
9 May - Audited FY25 results with Rs.507.25L preferential warrants allotment to non-promoters.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
a) VDPL is focused on establishing chain of Medical Stores with a brand name Ananya Pharma under the Venmax Drugs & Pharma Ltd, with the backing support of Formulations plant (Suzichem Labs). Currently, it has established 3 Shops & planning to expand them to 50 numbers around Hyderabad.
b) The company is developing oncology products in R&D. It is planning to establish a manufacturing UNIT with cGMP facility at Pharma Cluster at Hyderabad, to meet the export demand.